TOUJEO DOUBLESTAR 300 UNIT
INSULIN GLARGINE : 300 UNIT · DIN 02493373 · SANOFI-AVENTIS CANADA INC
Health Canada status: MARKETED
What is TOUJEO DOUBLESTAR?
TOUJEO DOUBLESTAR 300 UNIT contains INSULIN GLARGINE : 300 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02493373, held by SANOFI-AVENTIS CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 04-Feb-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TOUJEO DOUBLESTAR used for?
TOUJEO [insulin glargine injection (rDNA origin)] is indicated for once-daily subcutaneous administration in the treatment of adult and pediatric patients (6 years of age and older), with diabetes mellitus who require basal (long-acting) insulin for glycemic control.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02493373 |
|---|---|
| Brand name | TOUJEO DOUBLESTAR |
| Generic / active ingredient | INSULIN GLARGINE : 300 UNIT |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 300 UNIT |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | A10AE04 INSULIN GLARGINE |
| AHFS class | 91:04.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-Feb-2020 |
| Original market date | 2019-12-02 00:00:00 |
How is it administered?
Once-daily subcutaneous administration. Not for IV or IM use. Do not mix with other insulins. Monitor glucose and titrate based on individual needs. Dose adjustment needed when switching from Lantus.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
TOUJEO SoloSTAR: Disposable (prefilled) pen (1.5 mL) TOUJEO Double STAR: Disposable (prefilled) pen (3 mL)
Contraindications
Hypersensitivity to the drug or any ingredient; during episodes of hypoglycemia.
Warnings and precautions
Hypoglycemia is the most common adverse effect. Do not use IV/IM. Do not mix with other insulins. Check labels to avoid medication errors. Risk of hypokalemia and fluid retention with TZDs.
What can be used instead?
Other Canadian products sharing ATC code A10AE04 INSULIN GLARGINE. 8 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BASAGLAR | 100 UNIT | SOLUTION | ELI LILLY CANADA INC | MARKETED | DIN 02444844 |
| BASAGLAR | 100 UNIT | SOLUTION | ELI LILLY CANADA INC | MARKETED | DIN 02461528 |
| LANTUS | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02251930 |
| LANTUS | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02245689 |
| LANTUS | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02294338 |
| SEMGLEE | 100 UNIT | SOLUTION | BIOCON SDN.BHD | MARKETED | DIN 02526441 |
| TOUJEO SOLOSTAR | 300 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02441829 |
| BASAGLAR | 100 UNIT | SOLUTION | ELI LILLY CANADA INC | CANCELLED POST MARKET | DIN 02444852 |
| LANTUS | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED PRE MARKET | DIN 02280418 |
| LANTUS | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED PRE MARKET | DIN 02276410 |
Who else supplies INSULIN GLARGINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INSULIN GLARGINE appears in 441 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.